These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36504172)

  • 1. COVID-19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta-analysis.
    Lee MH; Li HJ; Wasuwanich P; Kim SE; Kim JY; Jeong GH; Park S; Yang JW; Kim MS; Yon DK; Lee SW; Koyanagi A; Jacob L; Kim EY; Cheon JH; Shin JI; Smith L
    Rev Med Virol; 2023 Mar; 33(2):e2414. PubMed ID: 36504172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
    Tripathi K; Godoy Brewer G; Thu Nguyen M; Singh Y; Saleh Ismail M; Sauk JS; Parian AM; Limketkai BN
    Inflamm Bowel Dis; 2022 Aug; 28(8):1265-1279. PubMed ID: 34718595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 outcomes in patients with inflammatory bowel diseases in Latin America: Results from SECURE-IBD registry.
    Queiroz NSF; Martins CA; Quaresma AB; Hino AAF; Steinwurz F; Ungaro RC; Kotze PG
    J Gastroenterol Hepatol; 2021 Nov; 36(11):3033-3040. PubMed ID: 34151470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.
    Brenner EJ; Ungaro RC; Gearry RB; Kaplan GG; Kissous-Hunt M; Lewis JD; Ng SC; Rahier JF; Reinisch W; Ruemmele FM; Steinwurz F; Underwood FE; Zhang X; Colombel JF; Kappelman MD
    Gastroenterology; 2020 Aug; 159(2):481-491.e3. PubMed ID: 32425234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: A systematic review and meta-analysis.
    Singh AK; Jena A; Kumar-M P; Sharma V; Sebastian S
    United European Gastroenterol J; 2021 Mar; 9(2):159-176. PubMed ID: 33210980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Low Immunoglobulin G Levels on Disease Outcomes in Patients with Inflammatory Bowel Diseases.
    Horton N; Wu X; Philpott J; Garber A; Achkar JP; Brzezinski A; Lashner BA; Shen B
    Dig Dis Sci; 2016 Nov; 61(11):3270-3277. PubMed ID: 27619393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesalazine in Inflammatory Bowel Disease and COVID-19: Hospitalization and Adverse In-Hospital Outcomes Based on Nationwide Data.
    Kjeldsen S; Nielsen J; Mertz Nørgård B; Kjeldsen J
    Inflamm Bowel Dis; 2022 Oct; 28(10):1513-1519. PubMed ID: 34849917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease.
    Choi YI; Kim TJ; Park DK; Chung JW; Kim KO; Kwon KA; Kim YJ
    Int J Colorectal Dis; 2019 Oct; 34(10):1713-1721. PubMed ID: 31471699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Wang Y; MacDonald JK; Hanauer S
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008870. PubMed ID: 27372735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.
    Qiu X; Ma J; Wang K; Zhang H
    Oncotarget; 2017 Jan; 8(1):1031-1045. PubMed ID: 27906680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
    Bezzio C; Armuzzi A; Furfaro F; Ardizzone S; Milla M; Carparelli S; Orlando A; Caprioli FA; Castiglione F; Viganò C; Ribaldone DG; Zingone F; Monterubbianesi R; Imperatore N; Festa S; Daperno M; Scucchi L; Ferronato A; Pastorelli L; Balestrieri P; Ricci C; Cappello M; Felice C; Fiorino G; Saibeni S;
    Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1432-1441. PubMed ID: 34694009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
    Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
    World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis.
    Alrashed F; Battat R; Abdullah I; Charabaty A; Shehab M
    BMJ Open Gastroenterol; 2021 Oct; 8(1):. PubMed ID: 34725056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of Elderly Onset Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Population-Based Cohort Studies.
    Rozich JJ; Dulai PS; Fumery M; Sandborn WJ; Singh S
    Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2437-2447.e6. PubMed ID: 32142940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis.
    Abdulla M; Mohammed N; AlQamish J; Mosli M
    Sci Rep; 2022 Dec; 12(1):21333. PubMed ID: 36494448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in Coronavirus disease - 19 vaccination related side effects in patients with ulcerative colitis and Crohn's disease in Japan.
    Miyazaki H; Watanabe D; Ito Y; Ikeda S; Okamoto N; Tokunaga E; Ku Y; Ooi M; Hoshi N; Kodama Y
    Indian J Gastroenterol; 2023 Oct; 42(5):701-707. PubMed ID: 37505394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine Safety Datalink project.
    Davis RL; Kramarz P; Bohlke K; Benson P; Thompson RS; Mullooly J; Black S; Shinefield H; Lewis E; Ward J; Marcy SM; Eriksen E; Destefano F; Chen R;
    Arch Pediatr Adolesc Med; 2001 Mar; 155(3):354-9. PubMed ID: 11231801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
    Burisch J
    Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.